Long title
A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-
Date receipt dossier
EudraCT number
2023-506259-97
Company / Sponsor
Janssen-Cilag International NV
Phase
Ib
Treated organism
Humans
Indication category
Cancer therapy
Disease
Relapsed or refractory B cell non-Hodgkin lymphoma
Therapeutic approach
Immunotherapy
Genetic modification
CD20 CAR
Method of transfer of nucleic acid of interest
Lentiviral vector
Administered biological material
Autologous T cells transduced with lentiviral vectors expressing CD20-CAR
Route of administration
Intravenous
Locations in Belgium
UZ Gent
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
JNJ-90009530